FXN and Friedreich ataxia: Therefore, comprehension of these mechanisms may help to design more adequate clinical trials in FRDA involving the administration of single drugs or combined therapies to simultaneously revert different downstream effects produced by frataxin deficiency, and in which proteins from the TRX family undoubtedly would play a prominent role.